Merck (MRK) and Eisai (ESALY) provided updates on two Phase 3 trials, LEAP-003 and LEAP-017 investigating Keytruda plus Lenvima. Merck and Eisai are discontinuing the Phase 3 LEAP-003 trial evaluating Keytruda plus Lenvima for the first-line treatment of adults with unresectable or metastatic melanoma. The decision is based on the recommendation of an independent Data Monitoring Committee, which reviewed data from a planned interim analysis and determined Keytruda plus Lenvima did not demonstrate an improvement in overall survival, one of the study’s dual primary endpoints, versus Keytruda alone.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on MRK:
- Moderna, Merck say mRNA cancer vaccine-KEYTRUDA combo granted PRIME designation
- MRK vs. BMY: Which Pharmaceutical Stock is Better?
- Merck, Proxygen enter collaboration, license agreement
- Padcev combo approval should alleviate concerns on Seagen deal, says BofA
- JPMorgan survey reveals ‘underappreciated pipeline opportunity’ for Merck